Sermorelin Dosage Guide: Research Protocol, Reconstitution & GHRH Timing (2026)

# Sermorelin Dosage Guide: Research Protocol, Reconstitution & GHRH Timing (2026)

> Research Use Only (RUO) Disclaimer: This article is intended strictly for educational and research information purposes. Sermorelin acetate is an FDA-approved compound studied in both clinical and laboratory research settings. Nothing in this guide constitutes medical advice, diagnosis, or treatment recommendations. Compounded sermorelin formulations are available only through licensed healthcare providers with a valid prescription. Always consult a qualified medical professional before initiating any peptide-based research protocol.

---

Sermorelin is one of the most clinically validated GHRH analogs available to researchers — the only peptide in its class with a long FDA approval history, a well-characterized pharmacokinetic profile, and decades of peer-reviewed dosing data. For investigators designing protocols involving sermorelin, the practical questions are specific: how much, when, how to reconstitute, and how long?

This guide addresses each of those questions with reference to the published literature and established clinical practice, in a research context. For a mechanistic overview of sermorelin, see the sermorelin research profile.

---

1. What Is Sermorelin? GHRH Analog Background

Sermorelin (sermorelin acetate; GRF 1-29; GHRH 1-29 NH₂) is a synthetic 29-amino-acid peptide representing the biologically active N-terminal fragment of endogenous human growth hormone-releasing hormone (GHRH). Full-length GHRH contains 44 residues; the 1-29 segment retains the receptor-binding domain necessary for agonism at pituitary GHRH receptors (GHRHRs).

FDA approval history:

• •1997 (NDA 019920): FDA approved Sermorelin Acetate Injection (Geref, Serono Laboratories) for treatment of idiopathic growth hormone deficiency in children with growth failure
• •Sermorelin is the earliest FDA-approved GHRH analog, establishing the regulatory and clinical baseline for all subsequent analogs (tesamorelin, etc.)
• •Clinical use has evolved to include off-label compounded formulations used in adult anti-aging and GH optimization research

Mechanism of action:

Upon subcutaneous (SC) administration, sermorelin binds GHRH receptors on anterior pituitary somatotropes, activating the Gs protein → adenylyl cyclase → cAMP cascade. This stimulates synthesis and pulsatile release of endogenous growth hormone (GH) — without directly supplying exogenous GH.

Critically, because sermorelin operates upstream of GH secretion, physiological feedback loops remain intact:

• •Somatostatin brake: High GH triggers hypothalamic somatostatin release, suppressing further secretion — this safeguard remains functional with sermorelin
• •IGF-1 negative feedback: Liver-derived IGF-1 (produced in response to GH) feeds back to suppress both GHRH release and pituitary GH output

Half-life: Approximately 10–20 minutes after SC injection. This short half-life produces a pulse of GH release that mimics physiological pulsatility, distinguishing it from longer-acting analogs like tesamorelin (~26 min) or CJC-1295 DAC (8–9 days).

For a full GHRH analog comparison, see GHRH Analogs Compared: Sermorelin vs CJC-1295 vs Tesamorelin.

---

2. Reconstitution: Bacteriostatic Water, Vial Sizes, and Step-by-Step Protocol

Research-grade sermorelin is supplied as a lyophilized (freeze-dried) white powder in sealed glass vials. It must be reconstituted before use.

Why Bacteriostatic Water (BAC Water)?

Bacteriostatic water (sterile water for injection with 0.9% benzyl alcohol) is the standard reconstitution solvent for multi-dose peptide research vials. Benzyl alcohol serves as a preservative that:

• •Inhibits microbial growth across multiple draws
• •Extends reconstituted shelf life to 14–28 days under refrigeration (2–8°C)
• •Maintains sterility through the protocol duration

Alternative: Sterile water for injection (no benzyl alcohol) may be used for single-dose research scenarios; discard unused reconstituted solution within 24 hours.

Reconstitution Calculations

Practical draw volume examples at 1,000 mcg/mL (using a 100-unit insulin syringe):

• •200 mcg dose → 0.20 mL = 20 units
• •300 mcg dose → 0.30 mL = 30 units
• •500 mcg dose → 0.50 mL = 50 units

Use the peptide reconstitution calculator to calculate precise draw volumes for any vial size and target dose. For sermorelin's full research profile, pricing, and supplier comparison, see /peptide/sermorelin.

Step-by-Step Reconstitution Protocol

1. Allow lyophilized vial to reach room temperature (~15–30 min)

2. Swab rubber stoppers of both the peptide vial and BAC water vial with 70% isopropyl alcohol; allow to air-dry 30 seconds

3. Draw the required BAC water volume into a sterile insulin syringe

4. Insert needle at 45° into the peptide vial, directing the solvent stream against the glass wall — not directly onto the powder cake. This prevents foaming and mechanical shear degradation of the peptide

5. Gently roll or swirl (do not shake vigorously) until powder is fully dissolved

6. Inspect the reconstituted solution: it should be clear and colorless. Cloudiness, particulates, or any coloration indicates degradation — discard

7. Label with reconstitution date; store refrigerated (2–8°C); discard after 28 days

---

3. Subcutaneous Injection Protocol

Sermorelin is administered subcutaneously. Standard research injection technique applies.

Recommended Injection Sites

The preferred SC injection sites for abdominal/periumbilical tissue are:

• •Abdomen: 1–2 inches away from the navel, alternating sides
• •Thigh: Outer third of the upper thigh
• •Upper arm: Posterior lateral aspect (less common, harder for self-administration)

Injection Procedure

1. Wash hands thoroughly; use sterile gloves if available

2. Wipe injection site with alcohol swab; allow to dry

3. Pinch a fold of skin between thumb and forefinger

4. Insert the insulin syringe needle at 45–90° (45° for leaner subjects; 90° for more subcutaneous tissue depth)

5. Aspirate briefly (not required with modern insulin syringes, but used in older protocols)

6. Inject slowly over 3–5 seconds

7. Withdraw needle; apply gentle pressure — do not rub, as this can disperse the peptide and cause irritation

8. Rotate injection sites with each administration to prevent lipodystrophy

Equipment Needed

• •100-unit insulin syringes (29–31 gauge, 0.5" needle length)
• •Bacteriostatic water (for reconstitution)
• •70% isopropyl alcohol swabs
• •Sterile gauze or cotton balls
• •Sharps disposal container

---

4. Sermorelin Dosage Ranges from Clinical and Research Literature

Dosage in the published literature varies by research objective, subject age and body weight, and whether the protocol is diagnostic (single acute test) or therapeutic/longitudinal.

Diagnostic Use (GH Stimulation Testing)

In pediatric GH deficiency assessment, sermorelin has been used diagnostically at:

• •Weight-based IV/SC dosing — used in acute GH stimulation/diagnostic testing protocols (Ranke MB, et al. European Journal of Pediatrics, 1986; PMID 2880720)
• •Peak GH response measured at 15, 30, 45, and 60 minutes post-injection

Research Protocol Dosage Ranges

Key reference: Once-daily subcutaneous GHRH-analog therapy at doses in this range has been studied in GH-deficient populations, with sustained IGF-1 responses reported over multi-month treatment (Thorner M, Rochiccioli P, et al., Geref International Study Group. Journal of Clinical Endocrinology & Metabolism, 1996; PMID 8772599). For a review of sermorelin's role in adult-onset GH insufficiency specifically, see Walker RF, Clinical Interventions in Aging, 2006; PMID 18046908.

Pediatric dosing (historical reference): FDA-approved doses for pediatric GH deficiency were 30 mcg/kg SC daily, typically ranging 300–1,500 mcg depending on body weight.

Weight-Based Dosing Considerations

Some research protocols adjust sermorelin dose by body weight, particularly in pediatric protocols. In adult research contexts, the literature more commonly uses fixed doses in the 200–500 mcg range, as GH pulse magnitude shows less linear weight-dependence in adults than in children.

---

5. Timing Relative to Sleep and Meals — The GHRH Timing Rationale

Timing is one of the most discussed variables in sermorelin protocol design. The rationale derives directly from the physiology of endogenous GH secretion.

Why Bedtime Administration Is Standard

Endogenous GH secretion follows a strongly circadian, pulsatile pattern. The largest and most reproducible GH pulse occurs during slow-wave sleep (SWS), typically within 60–90 minutes of sleep onset. This pulse accounts for approximately 60–70% of total daily GH secretion in young adults.

Sermorelin administered at or just before sleep onset can amplify this natural SWS-associated GH pulse by providing additional GHRH receptor stimulation at the time of greatest pituitary responsiveness. This is the primary rationale for bedtime SC administration.

Practical guidance:

• •Administer 30–60 minutes before sleep onset
• •Avoid eating within 2–3 hours of sermorelin administration — insulin released in response to a meal suppresses GH secretion via somatostatin. A fed state significantly reduces the magnitude of the sermorelin-stimulated GH pulse

Meal Timing Summary

Alternative Timing: Morning Administration

Some research protocols use morning administration to assess daytime IGF-1 response, or when bedtime administration is impractical. Morning protocols typically observe smaller GH pulses than bedtime equivalents, but may be useful for studying diurnal GH patterning or for protocols with multiple daily administrations.

---

6. Cycling Protocols in Research Contexts

Sermorelin research has explored both continuous and cycled administration strategies.

Continuous Protocol

In the FDA-approved pediatric indication, sermorelin was administered daily without cycling for months to years. Long-term downregulation of GHRH receptors has not been demonstrated to be a clinically significant issue at standard doses, though receptor desensitization is theoretically possible with continuous high-dose exposure.

Continuous daily dosing: Once-daily subcutaneous GHRH-analog administration over multi-month periods has demonstrated sustained IGF-1 responses without tachyphylaxis in the clinical literature (Thorner et al., JCEM, 1996; PMID 8772599; reviewed in Walker RF, Clinical Interventions in Aging, 2006; PMID 18046908).

Cycled Protocol (Research Design Consideration)

Some investigators employ cycled protocols to preserve receptor sensitivity and evaluate response after washout:

Note: These cycling protocols are research convention, not FDA-mandated requirements. The clinical evidence for superiority of cycled vs. continuous administration in adults is limited; cycling is primarily employed for study design reasons (endpoint measurement clean periods) rather than demonstrated efficacy advantage.

Sermorelin + GHRP Combination Protocols (Research Context)

Some research programs have evaluated sermorelin in combination with GHRPs (growth hormone-releasing peptides) such as GHRP-6 or ipamorelin, hypothesizing synergistic effects via dual receptor stimulation (GHRH-R and ghrelin receptor). Important: GHRPs such as GHRP-2, GHRP-6, and ipamorelin are not FDA-approved compounds. Any combined protocols would be conducted under RUO status only and represent investigational research.

---

7. Storage and Stability

Lyophilized (Pre-Reconstitution) Storage

Key principle: Keep lyophilized peptides dry and protected from light. Humidity and UV exposure accelerate degradation.

Reconstituted Solution Storage

Visual inspection check: Before each draw, inspect reconstituted sermorelin for clarity. Discard if cloudy, particulate, or discolored.

---

8. Sourcing and Quality Markers

What to Look for in Research-Grade Sermorelin

When sourcing sermorelin for research purposes, the following quality documentation should accompany the product:

1. HPLC Purity Analysis

High-Performance Liquid Chromatography (HPLC) measures chemical purity. Research-grade sermorelin should demonstrate:

• •≥98% purity by HPLC (some suppliers offer ≥99%)
• •A clean, single major peak — multiple peaks or broad peaks indicate impurities or degradation

2. Mass Spectrometry (MS) Confirmation

Mass spectrometry confirms molecular identity by verifying the molecular weight matches sermorelin's expected MW of approximately 3,357.9 Da. Any discrepancy indicates an incorrect or adulterated compound.

3. Certificate of Analysis (CoA)

A legitimate CoA will include:

• •Compound name and CAS number (sermorelin acetate: CAS 86168-78-7)
• •Lot number (traceable to specific synthesis batch)
• •Testing date
• •HPLC purity result with chromatogram
• •Mass spec confirmation with spectrum
• •Sterility test results (for injectable-grade products)
• •Peptide content (actual peptide mass as a % of total weight, accounting for counterions and water)

4. Third-Party Testing

Reputable suppliers provide CoAs from independent third-party laboratories, not internal testing only. Look for suppliers who routinely send samples to external analytical labs for confirmation.

Peptide Content vs. Purity

An important distinction: purity (HPLC, %) measures freedom from chemical impurities, while peptide content measures the actual mass of active peptide per gram of lyophilized powder. Peptide content accounts for:

• •Counterions (acetate salt weight)
• •Residual water content

A vial labeled "5 mg sermorelin" with 80% peptide content contains approximately 4 mg of actual sermorelin — this matters for dosage calculations. Premium suppliers will specify peptide content on the CoA; target ≥80% peptide content for research accuracy.

---

9. Price Comparison and Sourcing CTA

Sermorelin pricing across research suppliers varies significantly based on vial size, purity certification, and whether independent third-party testing is provided. For current pricing across verified suppliers:

→ Compare Sermorelin Prices Across Suppliers

Key price benchmarks to evaluate:

• •Per-mg cost: Normalize pricing to cost per mg for fair cross-supplier comparison
• •Purity guarantee: ≥98% HPLC is the minimum for research-grade material
• •CoA availability: Third-party tested CoAs should be downloadable, not just on request
• •BAC water inclusion: Some suppliers bundle reconstitution supplies; factor this into total protocol cost

For broader growth hormone peptide sourcing considerations, see the Best Growth Hormone Peptides 2026 Buyer's Guide.

---

10. Research Use Only (RUO) Disclaimers and Regulatory Context

Regulatory status: Sermorelin acetate holds FDA approval (NDA 019920; Geref) for the treatment of idiopathic growth hormone deficiency in children with growth failure. This approval covers pharmaceutical-grade sermorelin compounded by licensed pharmacies and prescribed by licensed physicians.

Research-grade sermorelin: Research-grade sermorelin sold by peptide research suppliers is supplied exclusively for laboratory and investigational research use — not for human clinical use without appropriate regulatory authorization. In the United States, research peptides sold under "RUO" designation are not intended for diagnostic, therapeutic, or prophylactic use in humans.

Key regulatory boundaries:

• •Research-grade peptides are not FDA-approved drugs and have not undergone the safety and efficacy review required for approved therapeutics
• •Their production is not subject to the cGMP pharmaceutical manufacturing standards that govern FDA-approved drugs
• •Purchase and possession for laboratory research is legal; use in human subjects outside of an approved clinical trial protocol requires IRB oversight and IND application (as applicable)

Medical advice disclaimer: This guide does not constitute medical advice. No information in this article should be interpreted as a recommendation for self-treatment, diagnosis, or medical intervention. Individuals seeking growth hormone therapy should consult a board-certified endocrinologist or anti-aging physician licensed in their jurisdiction.

---

Summary: Sermorelin Research Protocol at a Glance

Further reading:

• •Sermorelin Research Profile: FDA-Approved GHRH Analog
• •GHRH Analogs Compared: Sermorelin vs CJC-1295 vs Tesamorelin
• •CJC-1295 vs Sermorelin: Research Comparison Guide
• •Peptide Reconstitution Calculator
• •Sermorelin Research & Supplier Profile